Patient Characteristics
| Clinical parameter | Value |
| Total number of LVAD recipients | 57 |
| Mean (±SD) age at time of PET (y) | 56 ± 11 |
| Sex (%) | |
| Female | 14 |
| Male | 86 |
| Mean (±SD) LVAD carrying time before PET (d) | 814 ± 708 (range, 48–3,273) |
| Type of LVAD (%) | |
| HeartMate II (Abbott) | 24 |
| HeartMate III (Abbott) | 19 |
| HeartWare (Medtronic) | 41 |
| HeartWare II (Medtronic) | 16 |
| Underlying type of cardiomyopathy (%) | |
| Ischemic | 67 |
| Idiopathic dilated | 29 |
| Congenital | 4 |
| Antibiotic therapy at time of PET (%) | 88 |
| Type of antibiotic agent (%) | |
| Flucloxacillin/clindamycin | 34 |
| Meropenem | 19 |
| Other (ceftazidime, cefuroxime, ampicillin/sulbactam, linezolid, vancomycin, gentamycin, cotrimoxazole, piperacillin, ampicillin, daptomycin) | 47 |